STOCK TITAN

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Directors Regarding Bankruptcy Negotiations and Financial Disclosure Violations

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Negative)
Tags
Rhea-AI Summary
Buxton Helmsley Group accuses Mallinckrodt of accounting and securities fraud, highlights inaccurate representations of CFO
Positive
  • None.
Negative
  • Accusations of multibillion-dollar accounting and securities fraud scheme
  • Failure to make required write-downs of asset values
  • Violation of accounting standards and securities laws
  • Inaccurate representations of CFO

NEW YORK--(BUSINESS WIRE)-- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company’s Board of Directors, regarding the Company’s continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its August 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the “Commission”).

On March 17, 2023, BHG had issued a public report to the Company’s Board of Directors (also delivered to the Commission and U.S. Senate Finance Committee), which extensively outlaid and alleged an evidenced multibillion-dollar accounting and securities fraud scheme historically and presently occurring at the Company; uniquely, “strong[ly] evidence[d]” by the Company’s own prior-professed standard of determining the fair value of assets securing capital structure interests. Within that March 17, 2023, public report issued by BHG, it was thoroughly laid out how the Company had not only arguably been committing these violations of accounting standards and securities laws long before the Company’s Chapter 11 bankruptcy filing on October 12, 2020, but opted to apparently merely resume the scheme of concealing asset value depreciation expenses from the Company’s Commission-filed financial statements upon its emergence from reorganization proceedings, in violation of GAAP ASC 350/360 and Regulation S-X.

Since BHG’s March 17, 2023, public report, the Company has neither denied nor rebutted the “strong[ly] evidence[d]” (the Company’s own prior-professed evidentiary standard) apparent multibillion-dollar accounting and securities fraud scheme laid out therein.

Within the Letter today, BHG also highlighted how the Company has now corrected the inaccurate representations related to the licensing/credentials of Chief Financial Officer Bryan Reasons, but only after BHG was forced to publicly notify the Pennsylvania State Board of Accountancy within BHG’s April 28, 2023, follow-up letter to the Company (due to the Company’s apparent refusal to voluntarily correct the inaccurate representation after BHG’s initial March 17, 2023, public letter/report).

The Letter issued by BHG to the Company today, in addition to BHG’s March 17 and April 28, 2023, public correspondence, may be found at: https://www.buxtonhelmsley.com/mnk/

About Buxton Helmsley: The Buxton Helmsley Group, Inc. is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts, and other entities. The firm’s headquarters are in New York City.

Media:

Public Relations and Corp. Comm.

The Buxton Helmsley Group, Inc.

+1 (212) 561-5540, Option 4

press@buxtonhelmsley.com

Source: The Buxton Helmsley Group, Inc.

Mallinckrodt plc

NYSE:MNK

MNK Rankings

MNK Latest News

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
College Business Technology Park Cruiserath

About MNK

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit